Nurix Therapeutics, Inc. NRIX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s contract liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported contract liabilities of $7.59M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s contract liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s contract liabilities decreased by 68.6% year-over-year, from $24.15M to $7.59M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s contract liabilities?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s contract liabilities has grown at a -30.3% compound annual growth rate (CAGR), from $60.69M to $10.01M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.